Manager Quality Systems and Operational Workflow

Cleaner

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Andes

Angiex

Angiocrine Bioscience

Annexon Biosciences

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

Apollomics

Appia Bio

Apriori Bio

Aptevo Therapeutics

Aptose Biosciences

Aquinnah Pharmaceuticals

Aramis Biosciences

Arbor Biotechnologies

Arc Institute

Arcadia Science

Arcellx

Arctoris

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Accelevir Diagnostics is developing methods to detect rare analytes in infectious diseases. To reduce the spread of infectious diseases, assays are required that enable quick and accurate diagnostics. Combining expertise in virology, immunology and assay commercialization, Accelevir is creating scalable assays that can identify difficult to detect pathogens. The technology employed includes droplet-digital PCR, qPCR and sequencing that offer high sensitivity. Accelevir is initially focusing on advancing new assays for persistent HIV-1, the virus that causes AIDS, and other clinically important viral infections. These assays can be used to support basic science research and to evaluate clinical trials. 

<p>Accelevir Diagnostics is developing methods to detect rare analytes in infectious diseases. To reduce the spread of infectious diseases, assays are required that enable quick and accurate diagnostics. Combining expertise in virology, immunology and assay commercialization, Accelevir is creating scalable assays that can identify difficult to detect pathogens. The technology employed includes droplet-digital PCR, qPCR and sequencing that offer high sensitivity. Accelevir is initially focusing on advancing new assays for persistent HIV-1, the virus that causes AIDS, and other clinically important viral infections. These assays can be used to support basic science research and to evaluate clinical trials. </p>


Find a biotech startup job.